医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

CellProthera Raises 8.3 Million Euros

2017年02月02日 PM07:56
このエントリーをはてなブックマークに追加


 

MULHOUSE, France

CellProthera, a biotech company which offers the most advanced cell therapy for regeneration of the damaged heart muscle after myocardial infarction, announces it has raised €8,300,000 from private investors in 2016. These funds, supplements the 20 million€ raised during the previous rounds, and will enable CellProthera to pursue its scientific development, complete its Phase I/IIb clinical trial in Europe and prepare its Phase III in Europe and North America.

Carried out in three phases, 100% of the capital increase comes from family offices, some of them with a history of supporting CellProthera in previous rounds.
New stakeholders, specializing in innovation and ground-breaking technology, particularly in the medical sector, have expressed real enthusiasm for CellProthera, its progress and potential .

The funds raised will be used for three main programs:

1. Completion of the current phase I/IIb clinical trials. The company is also preparing the phase III trial, which involves setting up new cell therapy centers in Europe, the United States and Canada.

2. Development of an industrial automate. This device is at the core of the treatment offered by CellProthera; from a simple blood test, it generates, on an industrial scale and by cellular multiplication, a graft of CD34 + stem cells “ProtheraCytes®” which is re-injected into the patient.

3. CellProthera aims also to establish a foothold in Asia and will start a clinical trial in Singapore in 2017.

“With this new round, our investors have demonstrated their dedication and commitment to our project. The one million patients waiting for a therapy in Europe, the United States and Japan alone are grateful to them.

Philippe HENON         Jean-Claude JELSCH         Matthieu de KALBERMATTEN
Chairman & CSO Chairman of the Supervisory Board CEO

Additional information and visuals are available on request from the press department

The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170202005540/en/

CONTACT

OXYGEN
Aurélien SOHET, Tel. +33-(0)6-81-33-80-97
aurelien@oxygen-rp.com
or
OXYGEN
Jérémie
LOTZ,
Cell phone +33-(0)6-11-25-48-05
jlotz@oxygen-rp.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 十年磨一剑,Biosafe Defenses LLC宣布新突破性消毒剂
  • バイオセーフ・ディフェンシズ が10年にわたる研究を経て画期的な新消毒剤を発表
  • 第6届世界患者安全暨科技年度峰会将在英国伦敦召开
  • Avita Medical and BARDA Execute a US$24.3m Contract Option
  • CDISC and Cohen Veterans Bioscience Announce Public Review for Post Traumatic Stress Disorder Therapeutic Area User Guide